Pharmacovigilance (PV) Market

Pharmacovigilance (PV) Market

Pharmacovigilance Market to Reach US$ 20.1 bn by 2033, driven by The faster credit approval processes and ease of accessing the online platforms: Global Insight Services

New York, March 2024: According to a new research study by Global Insight Services (GIS), the global Pharmacovigilance Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 20.1 bn by 2033.

Pharmacovigilance is the science and activities related to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems. Passive surveillance is the most common type of pharmacovigilance activity. It is important because it can identify previously unknown adverse events. However, it has some limitations, such as under-reporting and reporting bias. Active surveillance is less common, but it is useful for monitoring drugs that are used to treat rare conditions. Experimental studies are the most reliable way to assess the safety of a new medicine, but they are usually only conducted during the development and approval process. Pharmacovigilance is a complex and ever-changing field. It requires close collaboration between healthcare professionals, patients and the pharmaceutical industry.

Request Sample Pages of this Research Report:

Pharmacovigilance Market: Key Trends and Drivers

The key drivers of pharmacovigilance (PV) market are the increasing number of clinical trials, the growing prevalence of chronic and life-threatening diseases, and the need for better patient safety.

The number of clinical trials has been increasing over the years as the pharmaceutical industry seeks to develop new and better treatments for various diseases. This has led to an increase in the number of patients being exposed to new drugs, which has in turn led to an increase in the need for PV.

The prevalence of chronic and life-threatening diseases is also a key driver of the PV market. As the population ages, the number of people suffering from chronic diseases such as cancer and heart disease is increasing. This is leading to a greater need for PV, as these patients are often taking multiple medications that need to be closely monitored for safety.

Finally, the need for better patient safety is also driving the PV market. In recent years, there have been a number of high-profile cases of patients being harmed by drugs that were not properly monitored. This has led to calls for better PV, which is helping to drive the market.

Pharmacovigilance Market: Restraints & Challenges

The key restraints and challenges in Pharmacovigilance (PV) market include the following:

  • Lack of awareness of PV among patients and healthcare professionals: There is a lack of awareness of PV among patients and healthcare professionals. This is a challenge because it can lead to underreporting of adverse events and lack of data for safety monitoring.
  • Lack of standardization: There is lack of standardization in PV, which is a challenge because it can lead to inconsistency in data collection and analysis.
  • Limited resources: PV requires significant resources, which can be a challenge for many organizations.
  • Lack of trained personnel: There is a lack of trained personnel in PV, which is a challenge because it can lead to errors in data collection and analysis.

Pharmacovigilance Market Report Findings

The phase IV segment is anticipated to hold a majority of the Pharmacovigilance Market size throughout the study period.

Based on the clinical trail phases, the Pharmacovigilance market is divided into Preclinical I, phase I, phase II, phase III, phase IV. The phase IV (post-marketing) segment led the overall market  share in 2023. These solutions act as an additional safety measure for the drugs undergoing clinical trials. Phase IV is an imperative stage of clinical trials as unsuspected adverse drug reactions can be detected in this stage. Therefore, the data collected and assessed during this stage is expected to be of the highest relevance owing to intensive drug testing on a large patient base of highest relevance after commercialization of the drug.

The phase III segment is expected to witness lucrative growth in the forecast period. Phase III trials are done to determine and establish the efficacy of drugs. These trials also provide additional information regarding possible drug interactions, drug safety, and effectiveness before the commercialization of the drug. The aforementioned factors are expected to boost revenue generation in the segment over the forecast period

The Contract outsourcing segment is anticipated to hold a majority of the Pharmacovigilance Market size throughout the study period.

By service provider, the industry is bifurcated into In-house, and Contract Outsourcing. Contract outsourcing held the dominant revenue share of over xx% in 2023 and is expected to witness the fastest CAGR in the forecast period. This can be attributed to the benefits associated with outsourcing such as risk mitigation, resource flexibility, reduction of upfront investments, and lower fixed costs. Contract outsourcing organizations provide solutions such as process design Standard Operating Procedure (SOP), PV audits, and other customized services.

The dynamic growth of the contract outsourcing segment can also be attributed to the rapidly emerging CROs providing end-to-end clinical trial solutions, especially in the emerging economies of Asia Pacific, such as India, China, and Japan, thereby enabling resources sharing, cost efficiency, resource flexibility, and expansion of operative capabilities. Outsourcing PV services is accompanied by benefits such as delivering services pertinent to highly complex regulatory requirements, helping to add scalability to accommodate growing product portfolios, and achieving aggressive cost targets. Contract outsourcing also helps reduce the complexity of clinical trials, allows faster approval of trials, and helps effective utilization of internal resources.

The Spontaneous reporting segment is likely to hold a dominant Pharmacovigilance Market share and grow at a substantial CAGR during the forecast period.

Based on Type of Reporting, the industry is categorized into Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, and EHR Mining. Spontaneous reporting held the largest share of over xx% in 2023 owing to wide usage in the detection of new, serious, and rare ADRs. Moreover, this segment serves as an efficient and inexpensive method. Wide usage of surveillance reports generated through this method by pharmaceutical industries and regulatory authorities is also responsible for the significant growth of the segment.

Cohort Event Monitoring (CEM) emerged as the second-largest segment in 2023 owing to its increasing application in the detection of a wide range of adverse clinical events. Conjugation of CEM with statistical tools and data mining systems such as longitudinal health records are responsible for the growing popularity of this type. It serves as an active form of surveillance method, which can also be used for new as well as older medicines, thus driving the segment.

The pharmaceuticals lending segment is anticipated to hold a majority of the Pharmacovigilance Market size throughout the study period.

Based on end-user, the Pharmacovigilance market is divided into Pharmaceuticals, Biotechnology Companies, Medical Device Manufacturers, and Others. In 2023, pharmaceuticals held the largest revenue share of over xx%. Outsourcing the pharmacovigilance process is practiced by pharma companies to avoid high upfront investments and fixed overhead costs, increase resource flexibility, and secure additional capacity. Outsourcing pharmacovigilance proves to be a cost-effective endeavor for small and medium-sized companies.

The biotechnology segment is anticipated to witness lucrative growth in the forthcoming years owing to increasing new product development activities in this sector. In recent years, drugs are being developed and consumed at increasingly high rates. The use of drugs over longer periods by a large population can lead to adverse effects not seen in clinical trials. For instance, Vioxx (an osteoarthritic/ acute pain medication) and Avandia (an anti-diabetic) were marketed for some time before a pattern of safety problems was detected with their use. The growing need for medical information among the regulatory authorities is also anticipated to drive the segment.

The North America region is estimated to exhibit the highest growth rate during the Pharmacovigilance Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America holds a major market share for pharmacovigilance and is expected to continue its stronghold for a few more years. Since pharmacovigilance activities are being shifted to contract research organizations (CROs) due to high costs, the pharmacovigilance approach in the United States is moving from a passive to a proactive role in the healthcare system. As per the Institute of Medicine report, by Christopher Cheney, published in March 2020, nearly 98,000 Americans died annually due to medication errors. Estimates of annual patient deaths due to medication errors have since risen steadily to 440,000 lives, which makes medication errors the country’s third-leading cause of death. Therefore, there is a need to modify the current protocols for quick communication between healthcare providers and the Food and Drug Administration. Since pharmacovigilance plays a vital role in drug assessment and prevention of adverse effects, the demand for such services is likely to increase in the near future.

Have a question for our analyst

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Pharmacovigilance market include Accenture, Cognizant, Laboratory Corporation of America Holdings, IBM Corporation, ArisGlobal, ICON plc., Capgemini, ITClinical, FMD K&L, and IQVIA among others.

Recent Developments in the Pharmacovigilance Market:

  • In December 2023, ArisGlobal, a prominent company in Life Sciences technology known for its LifeSphere® platform, has unveiled LifeSphere NavaX. This new offering is an advanced cognitive computing engine designed to speed up the digitization of research and development IT processes. It achieves this by utilizing sophisticated technologies such as Large Language Models (LLM) and Generative AI (Gen AI) to revolutionize pharmacovigilance (PV) activities.
  • In November 2023, Permira Advisers LLP has finalized the purchase of Ergomed plc for £703.1 million. Ergomed is a unique company specializing in Pharmacovigilance (PV) and contract research services (CRO), particularly focused on complex oncology and rare diseases. It is known for its excellent track record and customer-centric approach in delivering high-quality services. Ergomed operates in expanding markets that are seeing rising complexity, regulatory demands, and outsourcing trends. The company has enhanced its capabilities in both CRO and PV through organic growth and strategic acquisitions.
  • In November 2023, The National Agency for Food and Drug Administration and Control (NAFDAC) has announced that it has allocated a total budget of $2,305,695.03 for the Global Fund’s grant cycle 6. This allocation is aimed at enhancing operations and improving capacity, among other objectives. NAFDAC’s Director General, Prof Mojisola Adeyeye, shared during a press briefing in Abuja that a portion of this budget, specifically $36,965.00, has been dedicated to enhancing staff capabilities in pharmacovigilance strengthening and adverse drug reaction (ADR) monitoring.
  • In February 2022, Cognizant entered into a partnership with Medable Inc. to jointly deliver clinical research solutions based on Medable’s software-as-a-service platform for decentralized clinical trials.
  • In February 2022, LINK Medical and Viedoc entered into a partnership established by Viedoc and designed to improve trial efficiency for LINK Medical and its clients. The partnership allows for a continuous exchange of experience, needs, and ideas, as well as the testing of new features.
  • In November 2021, Deloitte and Sanofi collaborated on ConvergeHEALTH Safety, a next-generation artificial intelligence (AI) software-as-a-service adverse events case intake platform that will transform pharmacovigilance (PV) and address some of the industry’s most pressing operational safety issues.

Pharmacovigilance Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current Pharmacovigilance (PV) Market outlook and estimations from 2023 to 2033, which helps to recognize the prevalent opportunities.
  • The report also covers qualitative as well as quantitative analysis of the Pharmacovigilance (PV) Market in terms of revenue ($Million) and volume (Units).
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Pharmacovigilance (PV) industry.
  • A thorough analysis of market trends and restraints is provided.
  • By region as well as country, market analysis is also presented in this report.
  • The Pharmacovigilance (PV) Market Study comprises an analysis of 23 countries. The research also encompasses a segment analysis of every country in terms of value (USD Million) throughout the study period.
  • Analytical depiction of the Pharmacovigilance (PV) Market along with current trends and future estimations to depict imminent investment pockets. The overall Pharmacovigilance (PV) industry opportunity is examined by understanding profitable trends to gain a stronger foothold.
  • Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Pharmacovigilance (PV) Market are also analyzed.
  • The report also involves market strategy factors such as the ANSOFF Matrix, 4Ps Model, Demand-Supply Analysis, Competition Product Analysis, Recent Developments, Consumer Buying Interest, and Supply Chain Analysis among others.

Global Pharmacovigilance Market Segmentation

By Clinical Trial Phase

  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Service Provider

  • In-house
  • Contract Outsourcing

By Type of Reporting

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

By End User

  • Pharmaceuticals
  • Biotechnology Companies
  • Medical Device Manufacturers
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa
Key Players